Pulmonary Arterial Hypertension (PAH) Market to Exhibit Moderate Growth Rate Across the APAC Region During the Forecast Period, Asserts DelveInsight | Acceleron Pharma, Altavant Sciences, Complexa, Mezzion, Merck, PhaseBio, Resverlogix, and Ribomic

DelveInsight's "Pulmonary Arterial Hypertension (PAH) - Patient Pool Analysis, Market Size, and Market Forecast APAC, 2034" report provides comprehensive insights into the historical and projected patient burden, treatable patient population, and notable market trends across the APAC region (India, China, South Korea, Taiwan, and Australia), highlighting distinctions from established markets.

The APAC Pulmonary Arterial Hypertension market report also offers insights into current treatment patterns, emerging prominent players, market shares of approved drugs, and peak share estimates for upcoming therapies. It covers historical and forecasted Pulmonary Arterial Hypertension market size, share, and trends in the Asia-Pacific region (India, China, South Korea, Taiwan, and Australia) during the study period (2020-2034). Additionally, the report examines recent treatment practices, therapy compliance, and accessibility, identifying unmet needs and evaluating market potential.

Pulmonary Arterial Hypertension (PAH): An Overview
Pulmonary Hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during exercise, as measured by right heart catheterization. The World Health Organization (WHO) has divided PH into five groups based on similarities in pathophysiology, clinical presentation, and therapeutic options. Of these, Pulmonary Arterial Hypertension (PAH) belongs to WHO Group 1. It is a rare, progressive disorder characterized by hypertension in the pulmonary arteries for no apparent reason.

It was defined by the 6th World Symposium on Pulmonary Hypertension (WSPH) as a resting mean pulmonary artery pressure (mPAP) of 20 mm Hg or greater, a normal end-expiratory pulmonary artery wedge pressure (PAWP) less than or equal to 15 mm Hg, and a PVR of greater than or equal to 3 Wood units.

It is further classified by the WHO into the following types: idiopathic PAH (IPAH), heritable PAH (HPAH), drug- and toxin-induced PAH, and PAH associated with other diseases and disorders. The associated conditions include cirrhosis, HIV, congenital heart disease, and connective tissue diseases like scleroderma among others.

The initial symptoms include severe shortness of breath following exertion, excessive fatigue, weakness, chest pain, dizzy spells, and fainting episodes. Hemoptysis, hypotension, and hoarseness are also observed. In advanced stages, syncope, tachypnea, cyanosis, and hypertrophy resulting in diminished functioning of the right portion of the heart are observed, often leading to right heart failure.

Pulmonary Arterial Hypertension (PAH) Market Outlook (APAC Region)
The market for Pulmonary Arterial Hypertension (PAH) in the Asia Pacific region is witnessing significant advancements, driven by heightened awareness and improved treatment options. PAH, a rare and life-threatening condition, has historically posed challenges in diagnosis and management. However, recent years have seen remarkable progress with the introduction of targeted therapies such as endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Enhanced diagnostic techniques like echocardiography have improved accuracy, allowing for earlier intervention.

Collaborative efforts among healthcare professionals and advocacy groups have led to increased awareness and improved access to specialized care. Despite challenges like limited treatment centers and high costs, initiatives such as telemedicine and patient support programs are making strides. Ongoing research into novel therapeutic targets offers hope for further enhancing outcomes for individuals with PAH in the Asia Pacific region.

Get a Detailed Overview of the Evolving Pulmonary Arterial Hypertension Market Trends @
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension (PAH) Market
The Pulmonary Arterial Hypertension Market is poised for significant evolution, particularly within Asia-Pacific countries. This shift is underscored by the market outlook section of the report, which aims to enhance comprehension by delving into historical, present, and forecasted market projections. By examining the influence of both markets and emerging therapies, the report offers insights into the transformative forces at play. Furthermore, it conducts a thorough examination of the drivers, barriers, unmet needs, and emerging technologies within the Pulmonary Arterial Hypertension market landscape.

The report comprehensively outlines the market trends associated with every Pulmonary Arterial Hypertension drug currently available in the market and those in late-stage pipeline (i.e. Phase III stage) development. This thorough analysis encompasses various facets such as the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competitive landscape vis-à-vis other therapies, brand reputation, and their overall influence on the market dynamics. Furthermore, it incorporates insights from key opinion leaders, providing a holistic view of the market scenario.

Discover How the Pulmonary Arterial Hypertension Market Will Grow by 2034 @
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension (PAH) Epidemiology
The prevalence of Pulmonary Arterial Hypertension differs significantly across the APAC countries (India, China, South Korea, Taiwan, and Australia), influenced by a multitude of factors including genetics, demographics, lifestyle choices, and environmental elements. Within the report's epidemiology section, a comprehensive examination of patient burdens within each Asia-Pacific country is provided, encompassing historical, present, and projected trends. This analysis not only addresses the diagnosed and treated patient populations but also delves into sub-segments such as age-specific and gender-specific demographics, offering a nuanced understanding of the disease landscape within the region.

The Report Covers the Pulmonary Arterial Hypertension Epidemiology Segmented as -
• Total Prevalent Cases of PAH in the ASIA Pacific Region
• Total Diagnosed Cases of PAH in the ASIA Pacific Region
• Age-specific Cases of PAH in the ASIA Pacific Region
• Gender-specific Cases of PAH in the ASIA Pacific Region
• Class-specific Cases of PAH in the ASIA Pacific Region
• Subtype-specific Cases of PAH in the ASIA Pacific Region

Get Key Insights Into the Evolving Pulmonary Arterial Hypertension Epidemiology Trends @
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities
Numerous leading pharmaceutical and biotechnology firms are actively engaged in developing therapies for Pulmonary Arterial Hypertension. This section of the Pulmonary Arterial Hypertension market report offers detailed insights into each therapy approved within the APAC countries, provided the therapy retains patent protection or market exclusivity in at least one APAC nation. Notably, off-label, generic, and biosimilar treatments are consolidated within the preceding treatment section of the report. Within this section, both marketed and late-stage (Phase III and Phase II) pipeline drugs are scrutinized, while early-phase drugs are presented in tabular format for clarity and accessibility.

Every Pulmonary Arterial Hypertension drug chapter within the report will encompass a comprehensive overview, comprising detailed descriptions, clinical trial evaluations, insights into research and development initiatives, as well as analyses of agreements and collaborations pertinent to each drug. Moreover, the chapters will delve into approval status, patent particulars, and a thorough examination of the advantages and disadvantages associated with each drug. Additionally, the report covers the latest updates and news pertaining to each product, ensuring a well-rounded understanding of the current landscape surrounding these therapies.

Explore More About Ongoing Pipeline Development Activities in the Pulmonary Arterial Hypertension Market @
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pulmonary Arterial Hypertension (PAH) Therapeutics Assessment
Treatment of patients with PAH is based on a patient's vasoreactivity test and functional capacity, with the goal of increasing vasodilation of the pulmonary vasculature and decreasing mean pulmonary artery pressure (mPAP). Calcium channel blockers are recommended for those positive to the test while others are given therapies that include PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analog, and agonists. The marketed therapies approved for the treatment of PAH across various WHO Functional Classes (FC) include Johnson & Johnson/Nippon Shinyaku's UPTRAVI (selexipag) and OPSUMIT (macitentan), United Therapeutics' REMODULIN (treprostinil), TYVASO (treprostinil), and ORENITRAM (treprostinil), Bayer/Merck's ADEMPAS (riociguat). Certain combinations are also approved to address the shortcomings associated with monotherapies. However, none of these drugs are curative and have side effects associated with their long-term use. The market has a thirst for therapies that address the shortcomings associated with the current treatment regime.

Various therapies by Merck, United Therapeutics, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, and Tenax Therapeutics are expected to enter the market in the upcoming years. Even other companies like Enzyvant Therapeutics, Insmed, Cereno Scientific, Novartis, Gmax Biopharm, Vicore Pharma, and Aadi Bioscience among others have their products in early stages which have the potential to change the treatment regime for PAH.

Leading Companies in the Pulmonary Arterial Hypertension (PAH) Therapeutics Market Include
Acceleron Pharma, Altavant Sciences, Complexa, Galectin Therapeutics, Gmax Biopharm Australia, Gossamer Bio, Liquidia Technologies, Mezzion, Merck Sharp & Dohme, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Radikal Therapeutics, Resverlogix, and Ribomic are among the pharmaceutical and biotechnology companies actively engaged in the Pulmonary Arterial Hypertension Therapeutics Market.

Emerging and Marketed Pulmonary Arterial Hypertension Therapies Covered in the Report Include
• Sotatercept (MK-7962): Merck
• Ralinepag: United Therapeutics
• RT234 (vardenafil inhalation powder): Respira Therapeutics
• Seralutinib (GB002): Gossamer Bio
• YUTREPIA (inhaled dry powder formulation of treprostinil): Liquidia Technologies
• TNX-201: Tenax Therapeutics
And Many Others

Learn More About the Emerging Therapies and key Companies in the Pulmonary Arterial Hypertension Therapeutics Market @
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Pulmonary Arterial Hypertension Disease Background and Overview
8. APAC Pulmonary Arterial Hypertension Patient Pool Analysis
9. APAC Pulmonary Arterial Hypertension Patient Journey
10. Marketed Pulmonary Arterial Hypertension Therapies
11. Emerging Pulmonary Arterial Hypertension Therapies
12. Pulmonary Arterial Hypertension APAC Market Analysis
13. Access and Reimbursement Scenario
14. KOL's Views on Pulmonary Arterial Hypertension Market
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.